- Home
- CNF vs LSTA Comparison
CNF vs LSTA Comparison
Compare CNF & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNF | LSTA |
|---|---|---|
| Founded | 1999 | 1980 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 29.2M |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CNF | LSTA |
|---|---|---|
| Price | $2.85 | $3.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 2.8K | ★ 91.5K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | $252.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.37 | $1.81 |
| 52 Week High | $24.00 | $5.07 |
Technical Indicators
Market Signals| Indicator | CNF | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 27.42 |
| Support Level | $2.72 | $1.91 |
| Resistance Level | $5.13 | $4.95 |
| Average True Range (ATR) | 0.19 | 0.30 |
| MACD | 0.06 | -0.16 |
| Stochastic Oscillator | 25.87 | 19.83 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.